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Summary Classical models of tumorigenesis assume that the mutations which cause tumours to grow act in a cell-autonomous fashion. This
is not necessarily true. Sometimes tumour cells may adopt genetic strategies that boost their own replication and which also influence other
cells in the tumour, whether directly or as a side-effect. Tumour growth as a whole might be enhanced or retarded. We have used
mathematical models to study two non-autonomous strategies that tumour cells may use. First, we have considered the production by tumour
cells of an angiogenesis growth factor that benefits both the cell from which it originates and neighbouring cells. Second, we have analysed a
situation in which tumour cells produce autocrine-only or paracrine-only growth factors to prevent programmed cell death. In the angiogenesis
model, stable genetic polymorphisms are likely to occur between cells producing and not producing the growth factor. In the programmed cell
death model, cells with autocrine growth factor production can spread throughout the tumour. Production of paracrine-only growth factor is
never selected because it is 'altruistic' (that is of no benefit to the cell that makes the growth factor), despite being potentially beneficial to
tumour growth as a whole. No polymorphisms can occur in the programmed cell death model. Production of angiogenesis and other growth
factors in tumours may be under stable genetic, rather than epigenetic, control, with implications fortherapies aimed at such targets. Many of
the mutations observed in tumours may have non-autonomous effects.
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In classical models of tumorigenesis, mutations that promote
tumour growth are usually assumed to have cell-autonomous
modes of action (Armitage and Doll, 1954, 1957; Cairns, 1975;
Fisher, 1958; Loeb, 1991; Tomlinson and Bodmer, 1995). This
assumption may hold for many mutations, but it may not always
be valid. We suggest that some mutations might cause tumourcells
to adopt strategies that involve interacting with other cells in the
tumour. These interactions may take the form of a cell directly
influencing another cell, or they may be side-effects ofapparently
cell-autonomous action. We have constructed specific but simple
mathematical models to study the outcome when tumour cells
interact with one another.
The models below consider a small number of biologically
plausible situations and possible behaviours that tumour cells can
adopt in these situations. An individual cell's genotype leads
inevitably to the adoption of a particular strategy. Given genotype
frequencies and selective parameters, it is possible to determine
the benefits accruing to each behaviour and the frequencies with
which different genotypes interact. Changes in genotype
frequency can thus be calculated. At equilibrium, some genotypes
will be lost and others fixed in the population, or there will be an
internal point ofequilibrium (polymorphism).
All the models make a number ofassumptions. There is a large
population oftumour cells. These reproduce asexually. Population
size is not necessarily constant, but genotypes are considered in
terms of their frequencies rather than absolute cell numbers. The
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most important assumption is that genetic variation exists in
tumour cell strategies. Different, allelic tumour strategies are
present at specified frequencies within the tumour cell population.
The assumption of allelic determination of strategy is made for
convenience, although, in the absence of sexual reproduction, this
is probably valid even if different loci control each strategy.
Genotypes are distributed homogeneously throughout the tumour
and cells interact with their neighbours with probabilities depen-
dent solely on genotype frequency. This is a simplification of the
more complex spatial arrangements and interactions of tumour
cells that are likely to occur in reality.
In the models, intercellular interactions take place by produc-
tion ofspecific paracrine and/or autocrine growth factors. In some
cases, we assume that paracrine substances secreted by a cell
diffuse away from that cell and only affect its neighbours; in other
cases, we assume that the substance also has an autocrine action
and affects both the cell itselfand its neighbours. In addition, other
growth factors are assumed to be autocrine, i.e. affecting only the
cell that releases them. Detailed assumptions are given in the
descriptions ofthe models below. The manufacture and release of
all growth factors have some associated costs of production.
Factors such as shortages of nutrients and interactions with non-
tumour stromal cells are not considered explicitly.
The models presented below have several aims. First, and most
important, they provide a contrast with the cell-autonomous
effects of mutations that are assumed in classical models of
tumorigenesis. Second, they illustrate how tumour cells may
employ different strategies that affect other cells, thereby
favouring their own replication, perhaps atthe expense ofthe other
cells. Third, the models suggest which strategies are likely to be
the most successful in the tumour cell population, providing a
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theoretical basis for observed data. Fourth, the models can deter-
mine whether there are likely to be stable polymorphisms between
different cell strategies within tumours. As there is little empirical
basis for the values of the growth and selective parameters used
in the models, their conclusions are necessarily qualitative rather
than quantitative, and this fact should be borne in mind
throughout.
METHODS AND RESULTS
Model 1: Angiogenesis
This model considers production of a growth factor, such as an
angiogenesis promoter (Salahuddin et al, 1988; Leek et al, 1994).
The model is formally nearly identical to a number of other
biologically realistic situations, such as production of cytokines
to depress an anti-tumour immune response (Gorodilova and
Hollinshead, 1975). Its role is as a genetic alternative to models
which assume that production ofangiogenesis factors is caused by
inducible, epigenetic mechanisms. Here, only two cell strategies
are considered. The first of these (termed A-, frequency w) is
baseline. The alternative (A+, frequency v=l-w) is production of
the angiogenesis factor which has a cost of production (i) and
confers a benefit (j). The benefit accrues both to the cell itself and
to cells it encounters. The baseline cell-autonomous replication
rate is unity.
A matrix of fitnesses can be set up in which interactions
between cells are modelled as if they are 'encounters'. Here, the
fitness matrix is
Encounter
with
Fitness ofgenotype
A+ A-
A+ I-i+j 1+j
A- l-i+j 1
Thus, the new value of v in each succeeding generation (v') is
given by the probability of an A+ cell 'encountering' a cell of A+
or A- genotype, multiplied by the appropriate fitness in each case
and then normalized. Hence,
v' = (l-i+j)V/[(1-i+j)V+ (l+vj) ( -v)]
At equilibrium v'=v, and thus
l-i+j = (1-i+j)v + (l+vj)(l-v)
=> 0 = (v l)(l-i+j)- (v-l)(vj+l)
=> v = l-ilj
Thus, as long as j > i (i.e. the benefit of angiogenesis factor is
greater than its cost of production), there is a theoretical point of
internal equilibrium. Otherwise, strategy A+ is lost from the popu-
lation (v = 0) at equilibrium; no equilibrium exists at which v = 1,
as long as i > 0. Equilibrium frequencies are independent of the
initial value of v.
The stability of the internal equilibrium can be tested by deter-
mining whether the following inequality holds at equilibrium:
dv'fdv < 1
=> [(l-i+j)/(1+ (2j-1)V jV2)] - [(V(l-i+j)(2j-l-2djv))/((l+
(2j-l)v jV2)2)] < 1
In practice, this inequality holds for all equilibria (details not
shown).
Hence, the model suggests that genetic control ofthe production
of angiogenesis factors (or of immune response modulators) by
tumour cells is possible. Polymorphisms will occur commonly, as
it is plausible to assume that i <j. The benefits ofthe angiogenesis
factor must not be spread among too many cells that are 'non-
producers' lest the value ofj becomes dependent on the frequency
ofcells with strategy A+; ifthis occurs,j may be low relative to i,
when A+ is rare. This may be especially important ifangiogenesis
factor production arises as a new mutant in a large population of
tumour cells and may prevent the mutant from spreading.
Model 2: Programmed cell death
Here, prevention of programmed cell death (PCD) in tumour cells
normally depends on paracrine growth factors secretedby adjacent
cells (Kataoka et al, 1993; Wyllie, 1993; Harrington et al, 1994;
Isaacs, 1994; Boudreau et al, 1996; Panayiotidis et al, 1996). The
model assumes that the tumour has become too large for paracrine
growth factors from normal tissue to have a significant effect. In
the tumour, three genotypes are considered.
(1)A cell produces a growth factor to prevent PCD; this acts only
in a paracrine fashion (i.e. with no effect on the cell producing
the factor): frequency k.
(2)A cell produces a growth factor to prevent PCD; this acts
only in an autocrine fashion (or the cell becomes independent
ofgrowth factor, which amounts to the same strategy):
frequency m.
(3)A cell is dependent on paracrine growth factor but does not
produce it (i.e. the situation in which tumour cells are depen-
dent on normal tissue for growth factors): frequency n=1-k- m.
In addition:
(a)baseline fitness is unity;
(b)the cost ofproducing paracrine growth factor is a (a>O);
(c)the benefit ofreceiving paracrine growth factor is b (b>O); and
(d)the net cost-benefit ofproducing autocrine growth factor or
becoming independent ofgrowth factor is c (with c > 0
usually, ifthe autocrine growth factor is advantageous).
The matrix offitnesses consequent upon cell-cell interaction is
Encounter
with
Fitness ofgenotype
1 2 3
1 l-a+b I+b+c I+b
2 1-a l+c 1
3 l-a l+c 1
It is easiest to analyse this model by using the fact that fitnesses
must be equal at equilibrium. The assumption ofasexual reproduc-
tion allows this analysis to be performed. If we denote the fitness
ofstrategy (1) by w, etc., then
WI = k(l-a+b) + m(l-a) +n (l-a)
- (k+m+n)(1-a) + kb
- l-a+kb
w2 = k(l+b+c) +m(l+c) + n(l+c)
= (k+m+n)(I+c) + kb
- 1 +c+kb
1 +kb
For convenience, consider w, and w3 initially, as c may be either
positive or negative. It follows that
W3 > WI always, unless a = 0
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With a > 0, strategy (3) will always displace strategy (1) from the
population (or prevent it from spreading ifit enters the population).
It is then possible to consider strategies (2) and (3) alone. If
k = 0, fitnesses then become
W2 + c
W3 = +
With c > 0, strategy (2) will always displace strategy (3) from the
population; with c < 0, strategy (3) will always displace strategy
(2) from the population. (In the special case with c = 0, neither
genotype changes in frequency.) Simulations confirm these
conclusions and show that the boundary equilibria m = 0 (with c >
0) and n = 0 (with c < 0) are stable.
There is therefore strong selection for autocrine growth factor
production under this model, as long as the benefit outweighs the
cost (c > 0). If cost outweighs benefit, no cell produces growth
factor. No stable polymorphism between strategies can exist.
Strategy (1), 'altruistic' production of paracrine growth factor (at
net cost to individual tumour cells, but of benefit to the tumour as
a whole), never occurs, even if strategy (2) is absent, although
inspection readily shows that strategy (1) could lead to faster
overall tumour growth in some cases.
DISCUSSION
The models have examined situations in which tumour cells adopt
non-autonomous survival strategies and thus interact with one
another. Each strategy has been assumed to be under genetic
control, as distinct from behaviour determined epigenetically.
Interactions have been assumed, for simplicity, to occur between
individual cells; the results from the more complex interactions
found in reality can be inferred from the individual interactions.
There are several general conclusions from the models
presented here. The most basic of these is that genetically deter-
mined strategies that influence relationships between tumour cells
can occur in tumours. Such strategies can spread through the
tumour cell population from low initial frequencies to fixation or
some internal equilibrium value. In these models at least, the
strategies are beneficial to tumour growth as a whole, but the
tumour cell population does not necessarily achieve its optimum
replication rate. Small differences in genotype frequencies or para-
meters of selection may profoundly influence which strategies
succeed and which do not.
Model 1, of angiogenesis (or immune response depression),
shows that polymorphism between producers and non-producers of
angiogenesis factor can occur readily, independent of initial geno-
type frequencies. At equilibrium, the cost and net benefit of angio-
genesis factor production are equal. The mean replication rate is
raised by the production of angiogenesis factor or cytokine. It is
crucial to cells making angiogenesis factor that they themselves
benefit from it; otherwise, they will be lost from the population. We
have shown that genetic control ofangiogenesis factor (or cytokine)
production is possible and is an alternative to epigenetic models of
angiogenesis. Stable, polymorphic production of angiogenesis
factor is an alternative to epigenetic models of angiogenesis. This
finding has possible implications for anti-angiogenesis therapy.
Model 2, ofpreventing programmed cell death, differs crucially
from model I in that paracrine growth factors in model 2 only have
an effect on other cells. Model 2 also considers autocrine growth
factors, but there is assumed to be no overlap between the two
modes of growth factor action. In contrast to model 1, no internal
equilibria exist in model 2. Cells producing growth factor with a
paracrine effect only are always lost from the population, because
this behaviour is essentially altruistic. 'Altruistic' production of
growth factor, despite benefits for the tumour as a whole, is not
possible under the assumptions of model 2; it may be possible if a
model were to incorporate some form of 'kin selection'. In contrast
to cells making paracrine-only growth factor, producers of
autocrine growth factor usually spread to fixation. It is interesting
that autocrine growth factor production is observed in many
tumours (Sporn and Roberts, 1985; Hinkle and Kinsella, 1986;
Knabbe et al, 1987; Ensoli et al, 1989).
Although interactions between tumour cells and the stroma are
probably important in promoting the growth of some tumours
(Chung, 1995), relatively little is known about the importance
of relationships between tumour cells in vivo. Certainly, the
production of growth and angiogenesis factors has been observed
to be important. The models suggest that interactions between
tumour cells can readily occur in vivo, sometimes in stable poly-
morphisms. It follows that some of the mutations found in tumour
cells may not occur at oncogenes or tumour-suppressor genes, but
at loci involved in interactions with other cells in the tumour. More
complex models may reveal whether or not other features of
tumours, such as spontaneous regression, can be explained by non-
autonomy of tumour cell action.
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